FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.
Cytophage Technologies (TSXV: CYTO) has added bench strength to its board of directors this morning, adding a thirty year pharmaceutical and biotech executive to its board.
John Snisarenko has been appointed to the bacteriophage-focused firms board of directors. Snisarenko most recently served as chief commercial officer of Oyster Point Pharma, where he was responsible for the launch of Tyrvaya. Prior to this stint, he was responsible for commercializing Xiidra, a dry eye treatment, for Shire, where he was head of the Ophthalmics Franchise and group vice president, and was VP and franchise head within Genentech’s ophthalmology and rheumatology franchises. Over a billion dollars in sales is said to have been generated for each product within US markets under Snisarenko’s watch.
Sponsored · Altamira Gold Corp.
Snisarenko currently holds a B.Sc. in biochemistry, along with an MBA in marketing and international business from McGill University, and serves as an independent director on a number of boards for start-up and establishes companies in Canada and the US.
READ: Cytophage To Focus On Commercialization Efforts In 2024
“With the increasing threat of antimicrobial resistance (“AMR”) to global health, I am honoured to join the board of a true pioneer in bacteriophage solutions such as Cytophage. I am excited to bring my 30+ years of commercialization experience to the Cytophage board, and as the inaugural chair of their Commercialization Committee, I am very much looking forward to lending my skills to getting their products into the marketplace,” commented John Snisarenko on his appointment.
Cytophage Technologies last traded at $0.48 on the TSX Venture.
FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
